Chemomab Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Chemomab Therapeutics has a total shareholder equity of $16.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $20.9M and $4.6M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$19.38m |
| Equity | US$16.32m |
| Total liabilities | US$4.58m |
| Total assets | US$20.90m |
Recent financial health updates
Will Chemomab Therapeutics (NASDAQ:CMMB) Spend Its Cash Wisely?
Jan 10
Chemomab Therapeutics (NASDAQ:CMMB) Is In A Good Position To Deliver On Growth Plans
Sep 19Recent updates
Financial Position Analysis
Short Term Liabilities: CMMB's short term assets ($19.9M) exceed its short term liabilities ($4.3M).
Long Term Liabilities: CMMB's short term assets ($19.9M) exceed its long term liabilities ($230.0K).
Debt to Equity History and Analysis
Debt Level: CMMB is debt free.
Reducing Debt: CMMB has no debt compared to 5 years ago when its debt to equity ratio was 1.4%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CMMB has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CMMB has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 32.9% each year.